Loading
Life sciences · Journal article
F1000research · October 5, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Takotsubo syndrome (TTS) represents a diagnostic and therapeutic challenge in patients with cancer, in whom malignancy-related factors and anticancer therapies may coexist as potential predisposing or triggering factors. We report the case of a 68-year-old woman with chronic myeloid leukemia receiving dasatinib for two years who presented with acute heart failure. Initial echocardiography showed apical akinesia with a left ventricular ejection fraction of 38% and severely impaired global longitudinal strain (−6.3%). Coronary angiography revealed no significant obstructive coronary artery disease. Within two days, left ventricular function substantially improved, with an ejection fraction of 57% and global longitudinal strain of −14.2%. Cardiac magnetic resonance performed during this recovery phase demonstrated apical and mid-ventricular myocardial edema without late gadolinium enhancement, supporting the diagnosis of TTS. Although dasatinib-related myocardial and vascular effects provide biological plausibility for a potential contribution to TTS, a direct causal relationship could not be established. The long interval between treatment initiation and TTS onset, together with the coexistence of cancer-related predisposing factors, supports a multifactorial interpretation. Following multidisciplinary evaluation, dasatinib was continued under close cardiovascular monitoring. This case highlights that diagnostic certainty of TTS does not necessarily imply etiological certainty. In patients receiving long-term anticancer therapy, careful causal assessment is essential to distinguish a potential drug contribution from a multifactorial substrate and to avoid unnecessary discontinuation of effective cancer treatment.